Filing Flows › bioAffinity Technologies (BIAF) › Recalls, complaints & regulation

bioAffinity Technologies (BIAF): clinical trials

bioAffinity Technologies (BIAF) beyond its filings: 2 active clinical trials.

bioAffinity Technologies' latest quarter

bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does bioAffinity Technologies have?

2 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.